Search 

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.

Private investment firm

Heathcare PE fund

VC investment focus on healthy care

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion.  It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas.   Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.

For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders

healthcare VC

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services

2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.